drug
ivacaftor
Marketedupdated 6mo agoby $VERX Vertex, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval272 co-mentions · 91 sources
- drugORKAMBI246 co-mentions · 91 sources
- drugSYMDEKO (COPACKAGED)233 co-mentions · 91 sources
- drugKALYDECO226 co-mentions · 91 sources
- tagSmall Molecule136 co-mentions · 91 sources
- drugTRIKAFTA (COPACKAGED)38 co-mentions · 19 sources
- drug(ivacaftor + lumacaftor)20 co-mentions · 20 sources
- drug(elexacaftor + ivacaftor + tezacaftor) + ivacaftor19 co-mentions · 19 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.
indications
investigational
Cystic Fibrosis
all catalysts(21)
approval · 21
Mar 17, 2015
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Jun 8, 2016
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Feb 8, 2017
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
May 17, 2017
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Jul 31, 2017
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Feb 12, 2018
approval
$VERX17.30-0.46%
SYMDEKO (COPACKAGED) (IVACAFTOR) — FDA approval
ivacaftor
→
Aug 15, 2018
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Apr 29, 2019
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Jun 21, 2019
approval
$VERX17.30-0.46%
SYMDEKO (COPACKAGED) (IVACAFTOR) — FDA approval
ivacaftor
→
Dec 27, 2019
approval
$VERX17.30-0.46%
SYMDEKO (COPACKAGED) (IVACAFTOR) — FDA approval
ivacaftor
→
Sep 24, 2020
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Dec 21, 2020
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Dec 21, 2020
approval
$VERX17.30-0.46%
SYMDEKO (COPACKAGED) (IVACAFTOR) — FDA approval
ivacaftor
→
May 3, 2023
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Aug 3, 2023
approval
$VERX17.30-0.46%
SYMDEKO (COPACKAGED) (IVACAFTOR) — FDA approval
ivacaftor
→
Aug 3, 2023
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
May 22, 2025
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Sep 25, 2025
approval
$VERX17.30-0.46%
SYMDEKO (COPACKAGED) (IVACAFTOR) — FDA approval
ivacaftor
→
Sep 25, 2025
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Mar 17, 2026
approval
$VERX17.30-0.46%
KALYDECO (IVACAFTOR) — FDA approval
ivacaftor
→
Mar 17, 2026
approval
$VERX17.30-0.46%
SYMDEKO (COPACKAGED) (IVACAFTOR) — FDA approval
ivacaftor
→
Trials studying ivacaftor
- phase1Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
- phase2A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
- phase2Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
- phase2The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor
- phase1Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets
- phase2A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
- phase2Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 28, 2026
38 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (209)
- Apr 14, 2035formulationUS 10206877
- Apr 14, 2035formulationUS 10206877
- Apr 14, 2035formulationUS 11951212
- Aug 27, 2033patentUS 10272046*PED
- Aug 27, 2033patentUS 10272046*PED
- Aug 27, 2033patentUS 10272046*PED
- Aug 27, 2033patentUS 10272046*PED
- Aug 27, 2033patentUS 10272046*PED
- Aug 27, 2033patentUS 11147770*PED
- Aug 27, 2033patentUS 11147770*PED
- Aug 27, 2033patentUS 11147770*PED
- Aug 27, 2033patentUS 11147770*PED
- Aug 27, 2033patentUS 11147770*PED
- Aug 27, 2033patentUS 11752106*PED
- Aug 27, 2033patentUS 11752106*PED
- Aug 27, 2033patentUS 11752106*PED
- Aug 27, 2033patentUS 11752106*PED
- Aug 27, 2033patentUS 11752106*PED
- Aug 27, 2033patentUS 12214083*PED
- Aug 27, 2033patentUS 12214083*PED
- Aug 27, 2033patentUS 12214083*PED
- Aug 27, 2033patentUS 12214083*PED
- Aug 27, 2033patentUS 12214083*PED
- Aug 27, 2033patentUS 8883206*PED
- Aug 27, 2033patentUS 8883206*PED
- Aug 27, 2033patentUS 8883206*PED
- Aug 27, 2033patentUS 8883206*PED
- Aug 27, 2033patentUS 8883206*PED
- Jul 15, 2033method-of-use (U-3023)US 10058546
- Jul 15, 2033method-of-use (U-3022)US 10058546
- Jul 15, 2033method-of-use (U-2248)US 9012496
- Jul 15, 2033method-of-use (U-2248)US 9012496
- Feb 27, 2033formulationUS 10272046
- Feb 27, 2033formulationUS 10272046
- Feb 27, 2033formulationUS 10272046
- Feb 27, 2033formulationUS 10272046
- Feb 27, 2033formulationUS 10272046
- Feb 27, 2033formulationUS 11147770
- Feb 27, 2033formulationUS 11147770
- Feb 27, 2033formulationUS 11147770
- Feb 27, 2033formulationUS 11147770
- Feb 27, 2033formulationUS 11147770
- Feb 27, 2033formulationUS 11752106
- Feb 27, 2033formulationUS 11752106
- Feb 27, 2033formulationUS 11752106
- Feb 27, 2033formulationUS 11752106
- Feb 27, 2033formulationUS 11752106
- Feb 27, 2033formulationUS 12214083
- Feb 27, 2033formulationUS 12214083
- Feb 27, 2033formulationUS 12214083
- Feb 27, 2033formulationUS 12214083
- Feb 27, 2033formulationUS 12214083
- Feb 27, 2033formulationUS 8883206
- Feb 27, 2033formulationUS 8883206
- Feb 27, 2033formulationUS 8883206
- Feb 27, 2033formulationUS 8883206
- Feb 27, 2033formulationUS 8883206
- Jul 10, 2031compositionUS RE504534.6y
- Jul 10, 2031compositionUS RE504534.6y
- Mar 25, 2031formulationUS 100816214.3y
- Mar 25, 2031formulationUS 100816214.3y
- Mar 25, 2031formulationUS 115780624.3y
- Mar 25, 2031formulationUS 115780624.3y
- Feb 13, 2030patentUS 10646481*PED3.2y
- Feb 13, 2030patentUS 10646481*PED3.2y
- Feb 13, 2030patentUS 10646481*PED3.2y
- Feb 13, 2030patentUS 10646481*PED3.2y
- Feb 13, 2030patentUS 10646481*PED3.2y
- Feb 13, 2030patentUS 10646481*PED3.2y
- Feb 13, 2030patentUS 11564916*PED3.2y
- Feb 13, 2030patentUS 11564916*PED3.2y
- Feb 13, 2030patentUS 11564916*PED3.2y
- Feb 13, 2030patentUS 11564916*PED3.2y
- Feb 13, 2030patentUS 11564916*PED3.2y
- Feb 13, 2030patentUS 11564916*PED3.2y
- Feb 13, 2030patentUS 12458635*PED3.2y
- Feb 13, 2030patentUS 12458635*PED3.2y
- Feb 13, 2030patentUS 12458635*PED3.2y
- Feb 13, 2030patentUS 12458635*PED3.2y
- Feb 13, 2030patentUS 12458635*PED3.2y
- Feb 13, 2030patentUS 12458635*PED3.2y
- Aug 13, 2029formulationUS 106464812.7y
- Aug 13, 2029formulationUS 106464812.7y
- Aug 13, 2029formulationUS 106464812.7y
- Aug 13, 2029formulationUS 106464812.7y
- Aug 13, 2029formulationUS 106464812.7y
- Aug 13, 2029formulationUS 106464812.7y
- Aug 13, 2029formulationUS 106464812.7y
- Aug 13, 2029formulationUS 106464812.7y
- Aug 13, 2029method-of-use (U-3527)US 115649162.7y
- Aug 13, 2029method-of-use (U-3530)US 115649162.7y
- Aug 13, 2029method-of-use (U-3528)US 115649162.7y
- Aug 13, 2029method-of-use (U-3528)US 115649162.7y
- Aug 13, 2029method-of-use (U-3527)US 115649162.7y
- Aug 13, 2029method-of-use (U-3603)US 115649162.7y
- Aug 13, 2029method-of-use (U-3528)US 115649162.7y
- Aug 13, 2029method-of-use (U-3603)US 115649162.7y
- Aug 13, 2029formulationUS 124586352.7y
- Aug 13, 2029formulationUS 124586352.7y
- Aug 13, 2029formulationUS 124586352.7y
- Aug 13, 2029formulationUS 124586352.7y
- Aug 13, 2029formulationUS 124586352.7y
- Aug 13, 2029formulationUS 124586352.7y
- Aug 13, 2029formulationUS 124586352.7y
- Aug 13, 2029formulationUS 124586352.7y
- Feb 5, 2028patentUS 8324242*PED1.2y
- Feb 5, 2028patentUS 8324242*PED1.2y
- Feb 5, 2028patentUS 8324242*PED1.2y
- Feb 5, 2028patentUS 8324242*PED1.2y
- Feb 5, 2028patentUS 8324242*PED1.2y
- Feb 5, 2028patentUS 8324242*PED1.2y
- Nov 20, 2027patentUS 7495103*PED1.0y
- Nov 20, 2027patentUS 7495103*PED1.0y
- Nov 20, 2027patentUS 7495103*PED1.0y
- Nov 20, 2027patentUS 7495103*PED1.0y
- Nov 20, 2027patentUS 7495103*PED1.0y
- Nov 20, 2027patentUS 7495103*PED1.0y
- Nov 12, 2027method-of-use (U-2246)US 8415387357d
- Nov 12, 2027method-of-use (U-2246)US 8415387357d
- Aug 5, 2027method-of-use (U-2246)US 8324242258d
- Aug 5, 2027method-of-use (U-3609)US 8324242258d
- Aug 5, 2027method-of-use (U-1906)US 8324242258d
- Aug 5, 2027method-of-use (U-1906)US 8324242258d
- Aug 5, 2027method-of-use (U-2963)US 8324242258d
- Aug 5, 2027method-of-use (U-2246)US 8324242258d
- Aug 5, 2027method-of-use (U-1311)US 8324242258d
- Aug 5, 2027method-of-use (U-3609)US 8324242258d
- Jun 28, 2027patentUS 8410274*PED220d
- Jun 28, 2027patentUS 8410274*PED220d
- Jun 28, 2027patentUS 8410274*PED220d
- Jun 28, 2027patentUS 8410274*PED220d
- Jun 28, 2027patentUS 8410274*PED220d
- Jun 28, 2027patentUS 8410274*PED220d
- Jun 28, 2027patentUS 8754224*PED220d
- Jun 28, 2027patentUS 8754224*PED220d
- Jun 28, 2027patentUS 8754224*PED220d
- Jun 28, 2027patentUS 8754224*PED220d
- Jun 28, 2027patentUS 8754224*PED220d
- Jun 28, 2027patentUS 8754224*PED220d
- Jun 28, 2027patentUS 9670163*PED220d
- Jun 28, 2027patentUS 9670163*PED220d
- Jun 28, 2027patentUS 9670163*PED220d
- Jun 28, 2027patentUS 9670163*PED220d
- Jun 28, 2027patentUS 9670163*PED220d
- Jun 28, 2027patentUS 9670163*PED220d
- Jun 3, 2027compositionUS 7776905195d
- Jun 3, 2027compositionUS 7776905195d
- May 20, 2027compositionUS 7495103181d
- May 20, 2027compositionUS 7495103181d
- May 20, 2027compositionUS 7495103181d
- May 20, 2027compositionUS 7495103181d
- May 20, 2027compositionUS 7495103181d
- May 20, 2027compositionUS 7495103181d
- May 20, 2027compositionUS 7495103181d
- May 20, 2027compositionUS 7495103181d
- May 1, 2027compositionUS 7645789162d
- May 1, 2027compositionUS 7645789162d
- May 1, 2027method-of-use (U-2246)US 8598181162d
- May 1, 2027method-of-use (U-2246)US 8598181162d
- May 1, 2027compositionUS 8623905162d
- May 1, 2027compositionUS 8623905162d
- Apr 9, 2027formulationUS 10022352140d
- Apr 9, 2027formulationUS 10022352140d
- Apr 9, 2027compositionUS 10239867140d
- Apr 9, 2027compositionUS 10239867140d
- Apr 9, 2027compositionUS 11639347140d
- Apr 9, 2027compositionUS 11639347140d
- Apr 9, 2027formulationUS 9974781140d
- Apr 9, 2027formulationUS 9974781140d
- Jan 6, 2027patentUS 8354427*PED47d
- Jan 6, 2027patentUS 8354427*PED47d
- Jan 6, 2027patentUS 8354427*PED47d
- Jan 6, 2027patentUS 8354427*PED47d
- Jan 6, 2027patentUS 8354427*PED47d
- Jan 6, 2027patentUS 8354427*PED47d
- Dec 28, 2026formulationUS 841027438d
- Dec 28, 2026formulationUS 841027438d
- Dec 28, 2026formulationUS 841027438d
- Dec 28, 2026formulationUS 841027438d
- Dec 28, 2026formulationUS 841027438d
- Dec 28, 2026formulationUS 841027438d
- Dec 28, 2026formulationUS 841027438d
- Dec 28, 2026formulationUS 841027438d
- Dec 28, 2026compositionUS 875422438d
- Dec 28, 2026compositionUS 875422438d
- Dec 28, 2026compositionUS 875422438d
- Dec 28, 2026compositionUS 875422438d
- Dec 28, 2026compositionUS 875422438d
- Dec 28, 2026compositionUS 875422438d
- Dec 28, 2026compositionUS 875422438d
- Dec 28, 2026compositionUS 875422438d
- Dec 28, 2026formulationUS 967016338d
- Dec 28, 2026formulationUS 967016338d
- Dec 28, 2026formulationUS 967016338d
- Dec 28, 2026formulationUS 967016338d
- Dec 28, 2026formulationUS 967016338d
- Dec 28, 2026formulationUS 967016338d
- Dec 28, 2026formulationUS 967016338d
- Dec 28, 2026formulationUS 967016338d
- Dec 28, 2026formulationUS 993133438d
- Dec 28, 2026formulationUS 993133438d
- Jul 6, 2026method-of-use (U-1311)US 8354427
- Jul 6, 2026method-of-use (U-3021)US 8354427
- Jul 6, 2026method-of-use (U-3608)US 8354427
- Jul 6, 2026method-of-use (U-3608)US 8354427
- Jul 6, 2026method-of-use (U-1311)US 8354427
- Jul 6, 2026method-of-use (U-1905)US 8354427
- Jul 6, 2026method-of-use (U-2964)US 8354427
- Jul 6, 2026method-of-use (U-3021)US 8354427
FDA exclusivities (36)
- Nov 3, 2030PEDPediatric (6mo bonus)4.0y
- Nov 3, 2030PEDPediatric (6mo bonus)4.0y
- May 3, 2030ODE-435Orphan Drug (7y)3.5y
- May 3, 2030ODE-435Orphan Drug (7y)3.5y
- Nov 22, 2028PEDPediatric (6mo bonus)2.0y
- Nov 22, 2028PEDPediatric (6mo bonus)2.0y
- Nov 22, 2028PEDPediatric (6mo bonus)2.0y
- Nov 22, 2028PEDPediatric (6mo bonus)2.0y
- Nov 22, 2028PEDPediatric (6mo bonus)2.0y
- Jun 21, 2028PEDPediatric (6mo bonus)1.6y
- Jun 21, 2028PEDPediatric (6mo bonus)1.6y
- Jun 21, 2028PEDPediatric (6mo bonus)1.6y
- Jun 21, 2028PEDPediatric (6mo bonus)1.6y
- May 22, 2028M-14Method (3y)1.5y
- May 22, 2028M-14Method (3y)1.5y
- May 22, 2028M-14Method (3y)1.5y
- May 22, 2028M-14Method (3y)1.5y
- May 22, 2028M-14Method (3y)1.5y
- Dec 21, 2027ODE-338Orphan Drug (7y)1.1y
- Dec 21, 2027ODE-335Orphan Drug (7y)1.1y
- Dec 21, 2027ODE-335Orphan Drug (7y)1.1y
- Dec 21, 2027ODE-338Orphan Drug (7y)1.1y
- Dec 21, 2027ODE-338Orphan Drug (7y)1.1y
- Dec 21, 2027ODE-338Orphan Drug (7y)1.1y
- Nov 3, 2026PEDPediatric (6mo bonus)
- Nov 3, 2026PEDPediatric (6mo bonus)
- Oct 29, 2026PEDPediatric (6mo bonus)
- Oct 29, 2026PEDPediatric (6mo bonus)
- Oct 29, 2026PEDPediatric (6mo bonus)
- Jun 21, 2026ODE-247Orphan Drug (7y)
- Jun 21, 2026ODE-247Orphan Drug (7y)
- May 3, 2026NPPNew Product (3y)
- May 3, 2026NPPNew Product (3y)
- Apr 29, 2026ODE-236Orphan Drug (7y)
- Apr 29, 2026ODE-236Orphan Drug (7y)
- Apr 29, 2026ODE-236Orphan Drug (7y)
News(1)
- Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict loomsAnalysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.biospace · 1d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that